Skip to main content
SpringerLink
Log in

CCL20 Signaling in the Tumor Microenvironment

  • Chapter
  • First Online:
Tumor Microenvironment

Part of the book series: Advances in Experimental Medicine and Biology ((AEMB,volume 1231))

Abstract

CCL20, as a chemokine, plays an important role in rheumatoid arthritis, psoriasis, and other diseases by binding to its receptor CCR6. Recent 10 years’ research has demonstrated that CCL20 also contributes to the progression of many cancers, such as liver cancer, colon cancer, breast cancer, pancreatic cancer, and gastric cancer. This article reviews and discusses the previous studies on CCL20 roles in cancers from the aspects of its specific effects on various cancers, its remodeling on tumor microenvironment (TME), its synergistic effects with other cytokines in tumor microenvironment, and the specific mechanisms of CCL20 signal activation, illustrating CCL20 signaling in TME from multiple directions.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Bussard KM, Mutkus L, Stumpf K, Gomez-Manzano C, Marini FC (2016) Tumor-associated stromal cells as key contributors to the tumor microenvironment. Breast Cancer Res 18(1):84

    PubMed  PubMed Central  Google Scholar 

  2. Chen F, Zhuang X, Lin L, Yu P, Wang Y, Shi Y et al (2015) New horizons in tumor microenvironment biology: challenges and opportunities. BMC Med 13:45

    PubMed  PubMed Central  Google Scholar 

  3. Goubran HA, Kotb RR, Stakiw J, Emara ME, Burnouf T (2014) Regulation of tumor growth and metastasis: the role of tumor microenvironment. Cancer Growth Metastasis 7:9–18

    CAS  PubMed  PubMed Central  Google Scholar 

  4. Munn DH, Bronte V (2016) Immune suppressive mechanisms in the tumor microenvironment. Curr Opin Immunol 39:1–6

    CAS  PubMed  Google Scholar 

  5. Wang M, Zhao J, Zhang L, Wei F, Lian Y, Wu Y et al (2017) Role of tumor microenvironment in tumorigenesis. J Cancer 8(5):761–773

    CAS  PubMed  PubMed Central  Google Scholar 

  6. Beatty GL, Gladney WL (2015) Immune escape mechanisms as a guide for cancer immunotherapy. Clin Cancer Res 21(4):687–692

    CAS  PubMed  Google Scholar 

  7. Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF, Merad M et al (2018) Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med 24(5):541–550

    CAS  PubMed  PubMed Central  Google Scholar 

  8. Joyce JA, Fearon DT (2015) T cell exclusion, immune privilege, and the tumor microenvironment. Science 348(6230):74–80

    CAS  PubMed  Google Scholar 

  9. Powell DR, Huttenlocher A (2016) Neutrophils in the tumor microenvironment. Trends Immunol 37(1):41–52

    CAS  PubMed  Google Scholar 

  10. Ribas A (2015) Adaptive immune resistance: how cancer protects from immune attack. Cancer Discov 5(9):915–919

    CAS  PubMed  PubMed Central  Google Scholar 

  11. Scharping NE, Menk AV, Moreci RS, Whetstone RD, Dadey RE, Watkins SC et al (2016) The tumor microenvironment represses T cell mitochondrial biogenesis to drive intratumoral T cell metabolic insufficiency and dysfunction. Immunity 45(2):374–388

    CAS  PubMed  PubMed Central  Google Scholar 

  12. Heindl A, Nawaz S, Yuan Y (2015) Mapping spatial heterogeneity in the tumor microenvironment: a new era for digital pathology. Lab Invest 95(4):377–384

    PubMed  Google Scholar 

  13. Jimenez-Sanchez A, Memon D, Pourpe S, Veeraraghavan H, Li Y, Vargas HA et al (2017) Heterogeneous tumor-immune microenvironments among differentially growing metastases in an ovarian cancer patient. Cell 170(5):927–38.e20

    CAS  PubMed  PubMed Central  Google Scholar 

  14. McGranahan N, Swanton C (2017) Clonal heterogeneity and tumor evolution: past, present, and the future. Cell 168(4):613–628

    CAS  Google Scholar 

  15. Rucki AA, Foley K, Zhang P, Xiao Q, Kleponis J, Wu AA et al (2017) Heterogeneous stromal signaling within the tumor microenvironment controls the metastasis of pancreatic cancer. Cancer Res 77(1):41–52

    CAS  PubMed  Google Scholar 

  16. Kurahara H, Shinchi H, Mataki Y, Maemura K, Noma H, Kubo F et al (2011) Significance of M2-polarized tumor-associated macrophage in pancreatic cancer. J Surg Res 167(2):e211–e219

    PubMed  Google Scholar 

  17. Mantovani A, Marchesi F, Malesci A, Laghi L, Allavena P (2017) Tumour-associated macrophages as treatment targets in oncology. Nat Rev Clin Oncol 14(7):399–416

    CAS  PubMed  PubMed Central  Google Scholar 

  18. Quatromoni JG, Eruslanov E (2012) Tumor-associated macrophages: function, phenotype, and link to prognosis in human lung cancer. Am J Transl Res 4(4):376–389

    PubMed  PubMed Central  Google Scholar 

  19. Szebeni GJ, Vizler C, Kitajka K, Puskas LG (2017) Inflammation and cancer: extra- and intracellular determinants of tumor-associated macrophages as tumor promoters. Mediators Inflamm 2017:9294018

    PubMed  PubMed Central  Google Scholar 

  20. Yang L, Zhang Y (2017) Tumor-associated macrophages: from basic research to clinical application. J Hematol Oncol 10(1):58

    PubMed  PubMed Central  Google Scholar 

  21. Cui G, Yuan A, Sun Z, Zheng W, Pang Z (2018) IL-1beta/IL-6 network in the tumor microenvironment of human colorectal cancer. Pathol Res Pract 214(7):986–992

    CAS  PubMed  Google Scholar 

  22. Dougan M, Ingram JR, Jeong HJ, Mosaheb MM, Bruck PT, Ali L et al (2018) Targeting cytokine therapy to the pancreatic tumor microenvironment using PD-L1-specific VHHs. Cancer Immunol Res 6(4):389–401

    CAS  PubMed  PubMed Central  Google Scholar 

  23. Fisher DT, Appenheimer MM, Evans SS (2014) The two faces of IL-6 in the tumor microenvironment. Semin Immunol 26(1):38–47

    CAS  PubMed  PubMed Central  Google Scholar 

  24. Galdiero MR, Marone G, Mantovani A (2018) Cancer inflammation and cytokines. Cold Spring Harb Perspect Biol 10(8):a028662

    PubMed  Google Scholar 

  25. Korkaya H, Liu S, Wicha MS (2011) Breast cancer stem cells, cytokine networks, and the tumor microenvironment. J Clin Invest 121(10):3804–3809

    CAS  PubMed  PubMed Central  Google Scholar 

  26. Landskron G, De la Fuente M, Thuwajit P, Thuwajit C, Hermoso MA (2014) Chronic inflammation and cytokines in the tumor microenvironment. J Immunol Res 2014:149185

    PubMed  PubMed Central  Google Scholar 

  27. Liotti F, Collina F, Pone E, La Sala L, Franco R, Prevete N et al (2017) Interleukin-8, but not the related chemokine CXCL1, sustains an autocrine circuit necessary for the properties and functions of thyroid cancer stem cells. Stem Cells 35(1):135–146

    CAS  PubMed  Google Scholar 

  28. Long X, Ye Y, Zhang L, Liu P, Yu W, Wei F et al (2016) IL-8, a novel messenger to cross-link inflammation and tumor EMT via autocrine and paracrine pathways (Review). Int J Oncol 48(1):5–12

    CAS  PubMed  Google Scholar 

  29. Santander AM, Lopez-Ocejo O, Casas O, Agostini T, Sanchez L, Lamas-Basulto E et al (2015) Paracrine interactions between adipocytes and tumor cells recruit and modify macrophages to the mammary tumor microenvironment: the role of obesity and inflammation in breast adipose tissue. Cancers (Basel) 7(1):143–178

    CAS  Google Scholar 

  30. Wang Y, Chen J, Yang L, Li J, Wu W, Huang M et al (2019) Tumor-contacted neutrophils promote metastasis by a CD90-TIMP-1 juxtacrine-paracrine loop. Clin Cancer Res 25(6):1957–1969

    PubMed  Google Scholar 

  31. Boyle ST, Faulkner JW, McColl SR, Kochetkova M (2015) The chemokine receptor CCR6 facilitates the onset of mammary neoplasia in the MMTV-PyMT mouse model via recruitment of tumor-promoting macrophages. Mol Cancer 14:115

    PubMed  PubMed Central  Google Scholar 

  32. Kitamura T, Pollard JW (2015) Therapeutic potential of chemokine signal inhibition for metastatic breast cancer. Pharmacol Res 100:266–270

    CAS  PubMed  PubMed Central  Google Scholar 

  33. Nagarsheth N, Wicha MS, Zou W (2017) Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. Nat Rev Immunol 17(9):559–572

    CAS  PubMed  PubMed Central  Google Scholar 

  34. Armas-Gonzalez E, Dominguez-Luis MJ, Diaz-Martin A, Arce-Franco M, Castro-Hernandez J, Danelon G et al (2018) Role of CXCL13 and CCL20 in the recruitment of B cells to inflammatory foci in chronic arthritis. Arthritis Res Ther 20(1):114

    PubMed  PubMed Central  Google Scholar 

  35. Kim TG, Jee H, Fuentes-Duculan J, Wu WH, Byamba D, Kim DS et al (2014) Dermal clusters of mature dendritic cells and T cells are associated with the CCL20/CCR6 chemokine system in chronic psoriasis. J Invest Dermatol 134(5):1462–1465

    CAS  PubMed  Google Scholar 

  36. Lee AY, Korner H (2014) CCR6 and CCL20: emerging players in the pathogenesis of rheumatoid arthritis. Immunol Cell Biol 92(4):354–358

    CAS  PubMed  Google Scholar 

  37. Liu Y, Lagowski JP, Gao S, Raymond JH, White CR, Kulesz-Martin MF (2010) Regulation of the psoriatic chemokine CCL20 by E3 ligases Trim32 and Piasy in keratinocytes. J Invest Dermatol 130(5):1384–1390

    CAS  PubMed  PubMed Central  Google Scholar 

  38. Osuala KO, Sloane BF (2014) Many roles of CCL20: emphasis on breast cancer. Postdoc J 2(3):7–16

    PubMed  PubMed Central  Google Scholar 

  39. Nandi B, Pai C, Huang Q, Prabhala RH, Munshi NC, Gold JS (2014) CCR6, the sole receptor for the chemokine CCL20, promotes spontaneous intestinal tumorigenesis. PLoS One 9(5):e97566

    PubMed  PubMed Central  Google Scholar 

  40. Frick VO, Rubie C, Keilholz U, Ghadjar P (2016) Chemokine/chemokine receptor pair CCL20/CCR6 in human colorectal malignancy: an overview. World J Gastroenterol 22(2):833–841

    CAS  PubMed  PubMed Central  Google Scholar 

  41. Schutyser E, Struyf S, Van Damme J (2003) The CC chemokine CCL20 and its receptor CCR6. Cytokine Growth Factor Rev 14(5):409–426

    CAS  PubMed  Google Scholar 

  42. Williams IR (2006) CCR6 and CCL20: partners in intestinal immunity and lymphorganogenesis. Ann N Y Acad Sci 1072:52–61

    CAS  PubMed  Google Scholar 

  43. Acosta-Rodriguez EV, Rivino L, Geginat J, Jarrossay D, Gattorno M, Lanzavecchia A et al (2007) Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells. Nat Immunol 8(6):639–646

    CAS  PubMed  Google Scholar 

  44. Lyu M, Li Y, Hao Y, Lyu C, Huang Y, Sun B et al (2019) CCR6 defines a subset of activated memory T cells of Th17 potential in immune thrombocytopenia. Clin Exp Immunol 195(3):345–357

    CAS  PubMed  Google Scholar 

  45. Lee AYS, Korner H (2019) The CCR6-CCL20 axis in humoral immunity and T-B cell immunobiology. Immunobiology 224(3):449–454

    CAS  PubMed  Google Scholar 

  46. Godefroy E, Alameddine J, Montassier E, Mathe J, Desfrancois-Noel J, Marec N et al (2018) Expression of CCR6 and CXCR6 by gut-derived CD4(+)/CD8alpha(+) T-regulatory cells, which are decreased in blood samples from patients with inflammatory bowel diseases. Gastroenterology 155(4):1205–1217

    CAS  PubMed  Google Scholar 

  47. Skovdahl HK, Damas JK, Granlund AVB, Ostvik AE, Doseth B, Bruland T et al (2018) C-C Motif ligand 20 (CCL20) and C-C motif chemokine receptor 6 (CCR6) in human peripheral blood mononuclear cells: dysregulated in ulcerative colitis and a potential role for CCL20 in IL-1beta release. Int J Mol Sci 19(10):E3257

    PubMed  Google Scholar 

  48. Luo K, Zavala F, Gordy J, Zhang H, Markham RB (2017) Extended protection capabilities of an immature dendritic-cell targeting malaria sporozoite vaccine. Vaccine 35(18):2358–2364

    PubMed  Google Scholar 

  49. Campbell JJ, Ebsworth K, Ertl LS, McMahon JP, Newland D, Wang Y et al (2017) IL-17-Secreting gammadelta T cells are completely dependent upon CCR6 for homing to inflamed skin. J Immunol 199(9):3129–3136

    CAS  PubMed  Google Scholar 

  50. Cochez PM, Michiels C, Hendrickx E, Dauguet N, Warnier G, Renauld JC et al (2017) Ccr6 is dispensable for the development of skin lesions induced by imiquimod despite its effect on epidermal homing of IL-22-producing cells. J Invest Dermatol 137(5):1094–1103

    CAS  PubMed  Google Scholar 

  51. Planas D, Zhang Y, Monteiro P, Goulet JP, Gosselin A, Grandvaux N et al (2017) HIV-1 selectively targets gut-homing CCR6+CD4+ T cells via mTOR-dependent mechanisms. JCI Insight 2(15):93230

    PubMed  Google Scholar 

  52. Ranasinghe R, Eri R (2018) CCR6–CCL20-Mediated immunologic pathways in inflammatory bowel disease. Gastrointestinal Disorders 1(1):15–29

    Google Scholar 

  53. Skovdahl HK, Granlund A, Ostvik AE, Bruland T, Bakke I, Torp SH et al (2015) Expression of CCL20 and its corresponding receptor CCR6 is enhanced in active inflammatory bowel disease, and TLR3 mediates CCL20 expression in colonic epithelial cells. PLoS One 10(11):e0141710

    PubMed  PubMed Central  Google Scholar 

  54. Paulissen SM, van Hamburg JP, Dankers W, Lubberts E (2015) The role and modulation of CCR6+ Th17 cell populations in rheumatoid arthritis. Cytokine 74(1):43–53

    CAS  PubMed  Google Scholar 

  55. Kapur N, Mir H, Clark Iii CE, Krishnamurti U, Beech DJ, Lillard JW et al (2016) CCR6 expression in colon cancer is associated with advanced disease and supports epithelial-to-mesenchymal transition. Br J Cancer 114(12):1343–1351

    CAS  PubMed  PubMed Central  Google Scholar 

  56. Zhang XG, Song BT, Liu FJ, Sun D, Wang KX, Qu H (2016) CCR6 overexpression predicted advanced biological behaviors and poor prognosis in patients with gastric cancer. Clin Transl Oncol 18(7):700–707

    CAS  PubMed  Google Scholar 

  57. Huang F, Geng XP (2010) Chemokines and hepatocellular carcinoma. World J Gastroenterol 16(15):1832–1836

    CAS  PubMed  PubMed Central  Google Scholar 

  58. Ding X, Wang K, Wang H, Zhang G, Liu Y, Yang Q et al (2012) High expression of CCL20 is associated with poor prognosis in patients with hepatocellular carcinoma after curative resection. J Gastrointest Surg 16(4):828–836

    PubMed  Google Scholar 

  59. He H, Wu J, Zang M, Wang W, Chang X, Chen X et al (2017) CCR6(+) B lymphocytes responding to tumor cell-derived CCL20 support hepatocellular carcinoma progression via enhancing angiogenesis. Am J Cancer Res 7(5):1151–1163

    CAS  PubMed  PubMed Central  Google Scholar 

  60. Lee SK, Park KK, Kim HJ, Park J, Son SH, Kim KR et al (2017) Human antigen R-regulated CCL20 contributes to osteolytic breast cancer bone metastasis. Sci Rep 7(1):9610

    PubMed  PubMed Central  Google Scholar 

  61. Chen W, Qin Y, Wang D, Zhou L, Liu Y, Chen S et al (2018) CCL20 triggered by chemotherapy hinders the therapeutic efficacy of breast cancer. PLoS Biol 16(7):e2005869

    PubMed  PubMed Central  Google Scholar 

  62. Marsigliante S, Vetrugno C, Muscella A (2013) CCL20 induces migration and proliferation on breast epithelial cells. J Cell Physiol 228(9):1873–1883

    CAS  PubMed  Google Scholar 

  63. Marsigliante S, Vetrugno C, Muscella A (2016) Paracrine CCL20 loop induces epithelial-mesenchymal transition in breast epithelial cells. Mol Carcinog 55(7):1175–1186

    CAS  PubMed  Google Scholar 

  64. Hong GH, Kwon HS, Moon KA, Park SY, Park S, Lee KY et al (2016) Clusterin modulates allergic airway inflammation by attenuating CCL20-mediated dendritic cell recruitment. J Immunol 196(5):2021–2030

    CAS  PubMed  Google Scholar 

  65. Wang L, Liu Q, Sun Q, Zhang C, Chen T, Cao X (2008) TLR4 signaling in cancer cells promotes chemoattraction of immature dendritic cells via autocrine CCL20. Biochem Biophys Res Commun 366(3):852–856

    CAS  PubMed  Google Scholar 

  66. Charles J, Di Domizio J, Salameire D, Bendriss-Vermare N, Aspord C, Muhammad R et al (2010) Characterization of circulating dendritic cells in melanoma: role of CCR6 in plasmacytoid dendritic cell recruitment to the tumor. J Invest Dermatol 130(6):1646–1656

    CAS  PubMed  Google Scholar 

  67. Tanaka A, Sakaguchi S (2017) Regulatory T cells in cancer immunotherapy. Cell Res 27(1):109–118

    CAS  PubMed  Google Scholar 

  68. Plitas G, Konopacki C, Wu K, Bos PD, Morrow M, Putintseva EV et al (2016) Regulatory T cells exhibit distinct features in human breast cancer. Immunity 45(5):1122–1134

    CAS  PubMed  PubMed Central  Google Scholar 

  69. Liu C, Workman CJ, Vignali DA (2016) Targeting regulatory T cells in tumors. FEBS J 283(14):2731–2748

    CAS  PubMed  Google Scholar 

  70. Chen KJ, Lin SZ, Zhou L, Xie HY, Zhou WH, Taki-Eldin A et al (2011) Selective recruitment of regulatory T cell through CCR6-CCL20 in hepatocellular carcinoma fosters tumor progression and predicts poor prognosis. PLoS One 6(9):e24671

    CAS  PubMed  PubMed Central  Google Scholar 

  71. Liu J, Zhang N, Li Q, Zhang W, Ke F, Leng Q et al (2011) Tumor-associated macrophages recruit CCR6+ regulatory T cells and promote the development of colorectal cancer via enhancing CCL20 production in mice. PLoS One 6(4):e19495

    CAS  PubMed  PubMed Central  Google Scholar 

  72. Zou W, Restifo NP (2010) T(H)17 cells in tumour immunity and immunotherapy. Nat Rev Immunol 10(4):248–256

    CAS  PubMed  PubMed Central  Google Scholar 

  73. Miossec P, Korn T, Kuchroo VK (2009) Interleukin-17 and type 17 helper T cells. N Engl J Med 361(9):888–898

    CAS  PubMed  Google Scholar 

  74. Halwani R, Al-Muhsen S, Hamid Q (2013) T helper 17 cells in airway diseases: from laboratory bench to bedside. Chest 143(2):494–501

    CAS  PubMed  Google Scholar 

  75. Stockinger B, Omenetti S (2017) The dichotomous nature of T helper 17 cells. Nat Rev Immunol 17(9):535–544

    CAS  PubMed  Google Scholar 

  76. Amicarella F, Muraro MG, Hirt C, Cremonesi E, Padovan E, Mele V et al (2017) Dual role of tumour-infiltrating T helper 17 cells in human colorectal cancer. Gut 66(4):692–704

    CAS  PubMed  Google Scholar 

  77. Chang SH (2019) T helper 17 (Th17) cells and interleukin-17 (IL-17) in cancer. Arch Pharm Res 42(7):549–559

    CAS  PubMed  Google Scholar 

  78. Chi LJ, Lu HT, Li GL, Wang XM, Su Y, Xu WH et al (2010) Involvement of T helper type 17 and regulatory T cell activity in tumour immunology of bladder carcinoma. Clin Exp Immunol 161(3):480–489

    CAS  PubMed  PubMed Central  Google Scholar 

  79. Wang J, Cai D, Ma B, Wu G, Wu J (2011) Skewing the balance of regulatory T-cells and T-helper 17 cells in breast cancer patients. J Int Med Res 39(3):691–701

    CAS  PubMed  Google Scholar 

  80. Walch-Ruckheim B, Mavrova R, Henning M, Vicinus B, Kim YJ, Bohle RM et al (2015) Stromal fibroblasts induce CCL20 through IL6/C/EBPbeta to support the recruitment of Th17 cells during cervical cancer progression. Cancer Res 75(24):5248–5259

    PubMed  Google Scholar 

  81. Yu Q, Lou XM, He Y (2015) Preferential recruitment of Th17 cells to cervical cancer via CCR6-CCL20 pathway. PLoS One 10(3):e0120855

    PubMed  PubMed Central  Google Scholar 

  82. Kulbe H, Chakravarty P, Leinster DA, Charles KA, Kwong J, Thompson RG et al (2012) A dynamic inflammatory cytokine network in the human ovarian cancer microenvironment. Cancer Res 72(1):66–75

    CAS  PubMed  Google Scholar 

  83. Matsuo Y, Takeyama H, Guha S (2012) Cytokine network: new targeted therapy for pancreatic cancer. Curr Pharm Des 18(17):2416–2419

    CAS  PubMed  Google Scholar 

  84. Lasry A, Zinger A, Ben-Neriah Y (2016) Inflammatory networks underlying colorectal cancer. Nat Immunol 17(3):230–240

    CAS  PubMed  Google Scholar 

  85. Padoan A, Plebani M, Basso D (2019) Inflammation and pancreatic cancer: focus on metabolism, cytokines, and immunity. Int J Mol Sci 20(3):E676

    PubMed  Google Scholar 

  86. Cheng XS, Li YF, Tan J, Sun B, Xiao YC, Fang XB et al (2014) CCL20 and CXCL8 synergize to promote progression and poor survival outcome in patients with colorectal cancer by collaborative induction of the epithelial-mesenchymal transition. Cancer Lett 348(1-2):77–87

    CAS  PubMed  Google Scholar 

  87. Benkheil M, Van Haele M, Roskams T, Laporte M, Noppen S, Abbasi K et al (2018) CCL20, a direct-acting pro-angiogenic chemokine induced by hepatitis C virus (HCV): potential role in HCV-related liver cancer. Exp Cell Res 372(2):168–177

    CAS  PubMed  Google Scholar 

  88. Wang GZ, Cheng X, Li XC, Liu YQ, Wang XQ, Shi X et al (2015) Tobacco smoke induces production of chemokine CCL20 to promote lung cancer. Cancer Lett 363(1):60–70

    CAS  PubMed  Google Scholar 

  89. Chen CH, Chuang HC, Lin YT, Fang FM, Huang CC, Chen CM et al (2016) Circulating CD105 shows significant impact in patients of oral cancer and promotes malignancy of cancer cells via CCL20. Tumour Biol 37(2):1995–2005

    CAS  PubMed  Google Scholar 

  90. Beider K, Abraham M, Begin M, Wald H, Weiss ID, Wald O et al (2009) Interaction between CXCR4 and CCL20 pathways regulates tumor growth. PLoS One 4(4):e5125

    PubMed  PubMed Central  Google Scholar 

  91. Tsai ST, Chien IH, Shen WH, Kuo YZ, Jin YT, Wong TY et al (2010) ENO1, a potential prognostic head and neck cancer marker, promotes transformation partly via chemokine CCL20 induction. Eur J Cancer 46(9):1712–1723

    CAS  PubMed  Google Scholar 

  92. Yu X, Yuan Z, Yang Z, Chen D, Kim T, Cui Y et al (2018) The novel long noncoding RNA u50535 promotes colorectal cancer growth and metastasis by regulating CCL20. Cell Death Dis 9(7):751

    PubMed  PubMed Central  Google Scholar 

  93. Geismann C, Grohmann F, Dreher A, Hasler R, Rosenstiel P, Legler K et al (2017) Role of CCL20 mediated immune cell recruitment in NF-kappaB mediated TRAIL resistance of pancreatic cancer. Biochim Biophys Acta Mol Cell Res 1864(5):782–796

    CAS  PubMed  Google Scholar 

  94. Ignacio RM, Kabir SM, Lee ES, Adunyah SE, Son DS (2016) NF-kappaB-mediated CCL20 reigns dominantly in CXCR2-driven ovarian cancer progression. PLoS One 11(10):e0164189

    PubMed  PubMed Central  Google Scholar 

  95. Kucukkose C, Yalcin OO (2019) Effects of Notch signalling on the expression of SEMA3C, HMGA2, CXCL14, CXCR7, and CCL20 in breast cancer. Turk J Biol 43(1):70–76

    CAS  PubMed  PubMed Central  Google Scholar 

  96. Liu Y, Wang J, Ni T, Wang L, Wang Y, Sun X (2016) CCL20 mediates RANK/RANKL-induced epithelial-mesenchymal transition in endometrial cancer cells. Oncotarget 7(18):25328–25339

    PubMed  PubMed Central  Google Scholar 

  97. Tan H, Wang S, Zhao L (2017) A tumour-promoting role of Th9 cells in hepatocellular carcinoma through CCL20 and STAT3 pathways. Clin Exp Pharmacol Physiol 44(2):213–221

    CAS  PubMed  Google Scholar 

  98. Zeng W, Chang H, Ma M, Li Y (2014) CCL20/CCR6 promotes the invasion and migration of thyroid cancer cells via NF-kappa B signaling-induced MMP-3 production. Exp Mol Pathol 97(1):184–190

    CAS  PubMed  Google Scholar 

  99. Zhao C, Wang D, Tang L, Zhang Z, Li S, Qian M et al (2018) Stromal cell-derived CCL20 promotes tumor progression and osteolysis in giant cell tumor of bone. Cell Physiol Biochem 51(5):2472–2483

    CAS  PubMed  Google Scholar 

  100. Su S, Sun X, Zhang Q, Zhang Z, Chen J (2019) CCL20 Promotes ovarian cancer chemotherapy resistance by regulating ABCB1 expression. Cell Struct Funct 44(1):21–28

    PubMed  Google Scholar 

  101. Han G, Wu D, Yang Y, Li Z, Zhang J, Li C (2015) CrkL meditates CCL20/CCR6-induced EMT in gastric cancer. Cytokine 76(2):163–169

    CAS  PubMed  Google Scholar 

  102. Lu E, Su J, Zhou Y, Zhang C, Wang Y (2017) CCL20/CCR6 promotes cell proliferation and metastasis in laryngeal cancer by activating p38 pathway. Biomed Pharmacother 85:486–492

    CAS  PubMed  Google Scholar 

  103. Wang B, Shi L, Sun X, Wang L, Wang X, Chen C (2016) Production of CCL20 from lung cancer cells induces the cell migration and proliferation through PI3K pathway. J Cell Mol Med 20(5):920–929

    CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Fudan University Shanghai Cancer Center & Institutes of Biomedical Sciences, Shanghai Medical College, Shanghai, China

    Weilong Chen, Yuanyuan Qin & Suling Liu

  2. Key Laboratory of Breast Cancer in Shanghai, Innovation Center for Cell Signaling Network, Cancer Institute, Shanghai, China

    Weilong Chen, Yuanyuan Qin & Suling Liu

  3. Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, China

    Weilong Chen, Yuanyuan Qin & Suling Liu

Authors
  1. Weilong Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yuanyuan Qin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Suling Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Suling Liu .

Editor information

Editors and Affiliations

  1. Department of Radiology, Columbia University Medical Center, New York, NY, USA

    Alexander Birbrair

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Chen, W., Qin, Y., Liu, S. (2020). CCL20 Signaling in the Tumor Microenvironment. In: Birbrair, A. (eds) Tumor Microenvironment. Advances in Experimental Medicine and Biology, vol 1231. Springer, Cham. https://doi.org/10.1007/978-3-030-36667-4_6

Download citation

Publish with us

Policies and ethics

Search

Navigation